Compugen Ltd.

cgen.com

High-Tech Company
Public Company

(NASDAQ GS: CGEN), (NASDAQ GS: CGEN)

Graduated from: Iris Ventures Ltd.

TECH VERTICALS

Diagnostics, Immunotherapy, Life Sciences, MedTech, Pharmaceuticals

General Data

Sector	Biomed
Company Stage:	Revenue Growth
Established	1993
Number of Employees	80
Employees in Israel	60
Reg. Number:	abCDe

DESCRIPTION

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop first-in-class therapeutics in the field of cancer immunotherapy. The Company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets it has discovered computationally, including T cell immune checkpoints and additional early-stage immune-oncology programs focused largely on myeloid targets. Compugen's business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development.

TECHNOLOGY

Compugen discovers novel drug targets through a unique, predictive, computational process that combines human biology predictions derived from genome analysis combined with experimental and disease information derived from analysis of vast amounts of publicly available, as well as proprietary data. The comprehensive data analysis is designed to identify first-in-class drug target candidates, primarily in the field of immuno-oncology, which are difficult to identify using traditional computational or experimental approaches. An important aspect of Compugen’s predictive development efforts also includes the creation of three main technology platforms, LEADS, MED and LINKS, which integrate the Company’s scientific understandings and predictive models.

Products and Phases

Product	Phase
BAY 1905254/ILDR2	Phase I
ILDR2 is a novel immune checkpoint target with a unique mechanism of action discovered computationally by Compugen. While ILDR2 demonstrates an inhibitory effect on T cells, consistent with its role as an immune checkpoint ligand, preclinical data suggest that ILDR2 inhibition exerts its effects on immune cell priming rather than on directly enhancing immune cell killing effects in the tumor microenvironment.
COM701/PVRIG	Phase I
Compugen’s lead candidate, COM701, is a first-in-class immunotherapy targeting PVRIG, a novel immune checkpoint that our team computationally discovered and validated in preclinical studies. Clinical data of COM701, as a monotherapy and in combination with PD-1 blockers, have demonstrated initial signs of antitumor activity, with encouraging disease control rate, durability of responses and safety and tolerability in patients that have progressed or failed on many prior lines of therapy.
COM902/TIGIT	Phase I
COM902 is a therapeutic antibody against the immuno-oncology target TIGIT, a recently validated immune checkpoint. Compugen is ultimately developing COM902 to broaden the clinical potential of its PVRIG inhibitor, COM701 allowing to comprehensively block the DNAM axis by the parallel inhibition of TIGIT and PVRIG. With wholly owned candidates targeting two of the three pathways involved in its triple pathway hypothesis, both PVRIG and TIGIT, Compugen is able to maximally control its clinical strategy.
Myeloid Programs	Discovery
Myeloid cells, such as immunosuppressive macrophages, play a significant role in shaping the immunosuppressive tumor microenvironment and are critical for tumor development. Consequently, blocking myeloid cells may offer a complementary strategy to checkpoint inhibitors and provide new treatment solutions for non-responsive or relapsing patients as well as expand the patient population responsive to immunotherapies. Compugen’s discovery platform has identified multiple potential myeloid targets and the company is pursuing the research and development of novel therapeutics to further grow its pipeline.

ESTIMATED ANNUAL SALES

Year	Amount
2025	500
2024	490
2021	480
2020	470
2018	460
2016	450
2015	440
2014	430
2013	420

	TARGET MARKETS
	Pharmaceutical, Biotechnology and other Life Science Organizations

	BUSINESS MODEL
	B2B

AFFILIATION

Account ID	Affiliation Type	Name	Parent Name	Status
CA4752FC-1F7A-E111-AC59-00155D32A403		Compugen Ltd.
28C967EA-1F7A-E111-AC59-00155D32A403	Spin-off	Keddem Bioscience Ltd.	Compugen Ltd.	Ceased
6FC86FE4-1F7A-E111-AC59-00155D32A403	Spin-off	Evogene Ltd.	Compugen Ltd.
C9188384-59BF-E111-B9B4-00155D32A408	Spin-off	Neviah Genomics Ltd.	Compugen Ltd.	Ceased
946E1138-207A-E111-AC59-00155D32A403	Spin-off	Casterra AG Ltd.	Evogene Ltd.
BEFD8DDA-9AEC-E811-80F9-0050569A1018	Spin-off	AgPlenus Ltd.	Evogene Ltd.
39BE7B95-9448-E911-80FE-0050569A1018	Subsidiary	Lavie Bio Ltd.	Evogene Ltd.	Acquired/Merged
3B5B066D-7BBD-E711-80D7-00155D0B832C	Subsidiary	Biomica Ltd.	Evogene Ltd.
79A26E96-A056-E911-80FE-0050569A1018	Subsidiary	Canonic Ltd.	Evogene Ltd.	Ceased

SERVICE PROVIDERS

Company Name	Type
abC Defghij	Law Firm
abC Defghij	Accounting Firm

REMARKS

Date	Remark
	Compugen has established a small-molecule drug discovery affiliate - Keddem Bioscience, and an agricultural biotechnology affiliate - Evogene.

CONTACT INFO

Expand / Collapse All

Main Address: Holon, Israel

Address	Azrieli Center, 26 Harokmim St. Bldg D
City	Holon
Country	Israel
Zip	5885849

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

Branch Address: San Francisco, United States

Address	395 Oyster Point Boulevard Suite 307
City	San Francisco
State/Province	CA
Country	United States
Zip	94080

Contact Person	abC Defghij
Contact E-Mail	abC Defghij
Company E-mail	abC Defghij
Telephone	abC Defghij
Fax	abC Defghij

	MANAGEMENT

Key Executive

Name	Title	Previous Position
Dr. Anat Cohen-Dayag	President & CEO
Mr. David Silberman	CFO	Oramed (CFO)
Dr. Pierre Ferre	COO
Dr. Eran Ophir	CSO
Dr. Michelle Mahler	CMO
Dr. Yaron Turpaz	SVP & Senior Advisor, Computational Discovery
Dr. Zurit Levine	SVP, Technology Innovation
Ms. Dorit Amitay	VP, Human Resources
Mr. Simchon Faigler	Co-Founder	Biocceleration (CEO)
Mr. Eli Mintz	Co-Founder
Mr. Amir Natan	Co-Founder

	BOARD

Board

Member	Title	Affiliation
abC Defghij	Chairman	President & CEO, eGenesis
abC Defghij	Board Member	President & CEO, Compugen
abC Defghij	Board Member	Former EVP & Global Head of Oncology, Celgene Corporation
abC Defghij	Board Member	Managing Director & Chairman of the Investment Committee, MII Fund & Labs
abC Defghij	Board Member	Venture Partner, Medicxi

Public Offerings

Deal Date	Type of Offering	Exchange	Amount Raise	Valuation	Remarks
Mar. 12, 2020	Fourth Public Offering	NASDAQ GM	abCDe	abCDe	Includes realization of Greenshoe options ($4.3)
Mar. 01, 2014	Third Public Offering	NASDAQ GM	abCDe	abCDe
Dec. 30, 2009	Second Public Offering	NASDAQ GM	abCDe	abCDe	Through a Controlled Equity Offering facility. The shares were sold in the open market.
Jun. 17, 2009	Listing	NASDAQ GM	abCDe	abCDe
Jan. 07, 2002	Dual Listing	TASE	abCDe	abCDe
Aug. 11, 2000	IPO	NASDAQ GS	abCDe	abCDe	17/06/2009: Transferred to the NASDAQ Capital Market

	FINANCIAL ROUNDS

Total Capital Raised
abCDe

Financial Rounds

Numbers of Investors

Expand / Collapse All

Round

Date

Stage

Amount

Valuation

PIPE

Nov. 11, 2021

Revenue Growth

abCDe

PIPE

Oct. 11, 2018

Initial Revenues

abCDe

PIPE

Jun. 15, 2018

Initial Revenues

abCDe

PIPE

Dec. 21, 2011

Revenue Growth

abCDe

PIPE

Dec. 30, 2010

Revenue Growth

abCDe

Third Round

Jul. 17, 2000

Initial Revenues

abCDe

Second Round

Nov. 15, 1998

R&D

abCDe

First Round - Extended

Dec. 15, 1997

R&D

abCDe

First Round

Jul. 10, 1997

R&D

abCDe

Seed - Extended

Aug. 01, 1996

Seed

abCDe

Seed

Jan. 01, 1994

Seed

abCDe

	R&D Grants

Expand / Collapse All

Round

Date

Stage

Amount

Remarks

R&D Grant

Aug. 01, 2025

Initial Revenues

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe

R&D Grant

Jun. 24, 2009

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe	R&D grant ($0.4m); to support the company’s FPRL1 & TP programs during 2009

R&D Grant

Jun. 01, 2009

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Government Agency	abCDe	R&D grant ($0.5m); for support of certain on-going programs

R&D Grant

Jun. 01, 2006

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Bi-Lateral R&D Program	abCDe

R&D Grant

Jun. 28, 2005

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Bi-National Fund	abCDe	Co-op with Ortho-Clinical Diagnostics, Inc. (NJ)

R&D Grant

Jun. 01, 2005

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij*	Bi-Lateral R&D Program	abCDe

R&D Grant

Mar. 13, 2002

abCDe

* New investor

Investor	Type	Amount	Remarks
abC Defghij	Bi-National Fund	abCDe	Co-op with Diagnocure

	PORTFOLIO COMPANIES

Exits (1)

Company Name		Exit Type	Date Announced	Amount	Remarks
abC Defghij		Holdings Sold		abCDe

Historic Portfolio (2)

Company Name

Sector

Round/Deal Type

Date Announced

Investor Amount

Total Deal Amount

Remarks

Keddem Bioscience

Ceased to Operate

Biomed

Seed

01/01/2004

$5m

Neviah Genomics

Ceased to Operate

Biomed

First Round	13/01/2015	N/A	N/A
Seed	25/06/2012	N/A	N/A

Last Updated:	abCDe
IVC Number:	abCDe